Visium SA, a Swiss company specializing in AI and data solutions for regulated industries, has successfully completed its first institutional funding round. This funding, co-led by Columbus Venture Partners and Concentric, includes contributions from notable tech founders like Thomas Wolf and Sam Bourton.
Since its inception in 2018, Visium has expanded its workforce to 100 AI experts and delivered over 250 solutions to major clients in the life sciences sector, including Roche and Novartis. The funding will support its growth in Europe and the US, allowing the company to enhance its product offerings and team capabilities.
Columbus Venture Partners focuses on biotechnology investments, while Concentric is known for its support of software-driven businesses. The backing from these firms reflects a growing recognition of the transformative potential of generative AI in streamlining operations within the pharmaceutical and biotechnology industries.
This funding round is not only about financial support but also about strategic alignment with investors who share Visium's vision for innovation. CEO Alen Arslanagic emphasized the importance of building sustainable AI solutions that can drive significant impact in the industry. As Visium strengthens its board with experienced leaders, it aims to position itself at the forefront of AI-driven transformation in life sciences.